NCT03684811: A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

NCT03684811
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: IDH
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Chemotherapy, Immunotherapy, Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have IDH1-R132 gene-mutated tumor
Exclusions: 
https://ClinicalTrials.gov/show/NCT03684811

Comments are closed.

Up ↑